The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Open accessAbstract
BACKGROUND: Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with advanced epithelial cancers. This report summarizes the safety data from the overall safety population (OSP) and efficacy data, including additional disease cohorts not published previously. PATIENTS AND METHODS: Patients with refractory metastatic epithelial cancers received intravenous SG (8, 10, 12, or 18 mg/kg) on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity. Endpoints for the OSP included safety and pharmacokinetic parameters with investigator-evaluated objective response rate (ORR per RECIST 1.1), duration of response, clinical benefit rate, progression-free survival, and overall survival evaluated for cohorts (n > 10 patients) of small-cell lung, colorectal, esophageal, endometrial, pancreatic ductal adenocarcinoma, and castrate-resistant prostate cancer. RESULTS: In the OSP (n = 495, median age 61 years, 68% female; UGT1A1∗28 homozygous, n = 46; 9.3%), 41 (8.3%) permanently discontinued treatment due to adverse events (AEs). Most common treatment-related AEs were nausea (62.6%), diarrhea (56.2%), fatigue (48.3%), alopecia (40.4%), and neutropenia (57.8%). Most common treatment-related serious AEs (n = 75; 15.2%) were febrile neutropenia (4.0%) and diarrhea (2.8%). Grade ≥3 neutropenia and febrile neutropenia occurred in 42.4% and 5.3% of patients, respectively. Neutropenia (all grades) was numerically more frequent in UGT1A1∗28 homozygotes (28/46; 60.9%) than heterozygotes (69/180; 38.3%) or UGT1A1∗1 wild type (59/177; 33.3%). There was one treatment-related death due to an AE of aspiration pneumonia. Partial responses were seen in endometrial cancer (4/18, 22.2% ORR) and small-cell lung cancer (11/62, 17.7% ORR), and one castrate-resistant prostate cancer patient had a complete response (n = 1/11; 9.1% ORR). CONCLUSIONS: SG demonstrated a toxicity profile consistent with previous published reports. Efficacy was seen in several cancer cohorts, which validates Trop-2 as a broad target in solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Self-citationGoldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citationAntibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 366
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Self-citationUpregulation of Trop-2 quantitatively stimulates human cancer growth
Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A. L., Bonasera, V, Lattanzio, R., Lange, R. D., Weidle, U. H., Piantelli, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.36 · Cited by 331
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
Self-citationAghajanian, C., Sill, M. W., Darcy, K. M., Greer, B., McMeekin, D. S., Rose, P. G., Rotmensch, J., Barnes, M. N., Hanjani, P., & Leslie, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6397 · Cited by 326
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Self-citationCardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Self-citationCoats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Self-citationHuman TROP-2 is a tumor-associated calcium signal transducer
Rapani, E., Sacchetti, A., Corda, D., & Alberti, S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7 · Cited by 220
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Zeichner, S. B., Terawaki, H., & Gogineni, K. (2016) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s32783 · Cited by 196
Heist, R. S., Guarino, M. J., Masters, G., Purcell, W. T., Starodub, A. N., Horn, L., Scheff, R. J., Bardia, A., Messersmith, W. A., Berlin, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1894 · Cited by 193
Self-citationGoldenberg, D. M., & Sharkey, R. M. (2019) · mAbs · doi:10.1080/19420862.2019.1632115 · Cited by 164
Self-citationKalinsky, K. M., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O’Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 163
Self-citationGray, J. E., Heist, R. S., Starodub, A. N., Camidge, D. R., Kio, E. A., Masters, G. A., Purcell, W. T., Guarino, M. J., Misleh, J., Schneider, C. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0933 · Cited by 162
Self-citationNovel antibody–drug conjugates for triple negative breast cancer
Nagayama, A., Vidula, N., Ellisen, L. W., & Bardia, A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920915980 · Cited by 157
Self-citationSacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Goldenberg, D. M., & Sharkey, R. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1757067 · Cited by 141
Self-citationMilatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Govindan, S. V., Cardillo, T. M., Sharkey, R. M., Tat, F. T., Gold, D. V., & Goldenberg, D. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1170 · Cited by 136
Self-citationNew therapies for advanced, recurrent, and metastatic endometrial cancers
Makker, V., Green, A. K., Wenham, R. M., Mutch, D. G., Davidson, B. A., & Miller, D. S. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0056-7 · Cited by 111
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
Bekaii‐Saab, T., Kim, R. D., Kim, T. W., O’Connor, J. M., Strickler, J. H., Malka, D., Bianchi, A. S., Bi, F., Yamaguchi, K., Yoshino, T., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.002 · Cited by 88
Tagawa, S. T., Faltas, B. M., Lam, E. T., Saylor, P. J., Bardia, A., Hajdenberg, J. J., Morgans, A. K., Lim, E. A., Kalinsky, K. M., Simpson, P. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.354 · Cited by 84
Self-citationBignotti, E., Zanotti, L., Calza, S., Falchetti, M., Lonardi, S., Ravaggi, A., Romani, C., Todeschini, P., Bandiera, E., Tassi, R. A., et al. (2012) · BMC Clinical Pathology · doi:10.1186/1472-6890-12-22 · Cited by 82
Self-citationAdvances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
Stanchina, M., Soong, D., Zheng-Lin, B., Watts, J. M., & Taylor, J. (2020) · Cancers · doi:10.3390/cancers12113225 · Cited by 80
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
Lopez, S., Perrone, E., Bellone, S., Bonazzoli, E., Zeybek, B., Han, C., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Bianchi, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27342 · Cited by 51
Self-citationPerrone, E., Manara, P., Lopez, S., Bellone, S., Bonazzoli, E., Manzano, A., Zammataro, L. A., Bianchi, A., Zeybek, B., Buza, N., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12627 · Cited by 49
Self-citationHan, C., Perrone, E., Zeybek, B., Bellone, S., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Feinberg, J., Haines, K. E., Karger, M. E. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.018 · Cited by 44
Self-citationHattori, M., & Iwata, H. (2018) · Chinese Clinical Oncology · doi:10.21037/cco.2018.05.01 · Cited by 34
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
Normann, M., Türzer, M., Diep, L. M., Oldenburg, J., Gajdzik, B., Solheim, O., & Rud, E. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e56 · Cited by 28
Cited by
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortes, J., Soria, J., & Curigliano, G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 385
Self-citationRecent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Metadata
- Authors
- Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., O'Shaughnessy, J., Gray, J. E., Komiya, T., Lang, J. M., Chang, J. C., Starodub, A., Goldenberg, D. M., Sharkey, R. M., Maliakal, P., Hong, Q., Wegener, W. A., Goswami, T., & Ocean, A. J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 32
- Issue
- 6
- Pages
- 746-756
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3136196685
- Cited by
- 400
- References
- 33
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.